JP2015505477A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015505477A5 JP2015505477A5 JP2014555736A JP2014555736A JP2015505477A5 JP 2015505477 A5 JP2015505477 A5 JP 2015505477A5 JP 2014555736 A JP2014555736 A JP 2014555736A JP 2014555736 A JP2014555736 A JP 2014555736A JP 2015505477 A5 JP2015505477 A5 JP 2015505477A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- gene
- light chain
- chain constant
- rodent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000623 proteins and genes Proteins 0.000 claims description 103
- 241000283984 Rodentia Species 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 18
- 150000007523 nucleic acids Chemical group 0.000 claims description 16
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 15
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 14
- 210000004027 cell Anatomy 0.000 claims description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 13
- 239000000427 antigen Substances 0.000 claims description 13
- 102000036639 antigens Human genes 0.000 claims description 13
- 108091007433 antigens Proteins 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 12
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 10
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 9
- 230000004048 modification Effects 0.000 claims description 9
- 238000012986 modification Methods 0.000 claims description 9
- 108091008324 binding proteins Proteins 0.000 claims description 8
- 238000003780 insertion Methods 0.000 claims description 8
- 230000037431 insertion Effects 0.000 claims description 8
- 238000011144 upstream manufacturing Methods 0.000 claims description 8
- 108700005091 Immunoglobulin Genes Proteins 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims description 2
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims description 2
- 102000025171 antigen binding proteins Human genes 0.000 claims description 2
- 108091000831 antigen binding proteins Proteins 0.000 claims description 2
- 230000008030 elimination Effects 0.000 claims description 2
- 238000003379 elimination reaction Methods 0.000 claims description 2
- 210000004408 hybridoma Anatomy 0.000 claims description 2
- 210000001161 mammalian embryo Anatomy 0.000 claims description 2
- 102000023732 binding proteins Human genes 0.000 claims 4
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 claims 1
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 claims 1
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 claims 1
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 claims 1
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 claims 1
- 102100022964 Immunoglobulin kappa variable 3-20 Human genes 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 238000012239 gene modification Methods 0.000 claims 1
- 230000005017 genetic modification Effects 0.000 claims 1
- 235000013617 genetically modified food Nutrition 0.000 claims 1
- 102000014914 Carrier Proteins Human genes 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261593463P | 2012-02-01 | 2012-02-01 | |
| US61/593,463 | 2012-02-01 | ||
| US201261677538P | 2012-07-31 | 2012-07-31 | |
| US61/677,538 | 2012-07-31 | ||
| PCT/US2013/024295 WO2013116609A1 (en) | 2012-02-01 | 2013-02-01 | Humanized rodents that express heavy chains containing vl domains |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018022012A Division JP6698718B2 (ja) | 2012-02-01 | 2018-02-09 | Ｖｌドメインを含む重鎖を発現するヒト化齧歯動物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015505477A JP2015505477A (ja) | 2015-02-23 |
| JP2015505477A5 true JP2015505477A5 (enExample) | 2016-03-03 |
Family
ID=47714588
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014555736A Withdrawn JP2015505477A (ja) | 2012-02-01 | 2013-02-01 | Ｖｌドメインを含む重鎖を発現するヒト化齧歯動物 |
| JP2018022012A Active JP6698718B2 (ja) | 2012-02-01 | 2018-02-09 | Ｖｌドメインを含む重鎖を発現するヒト化齧歯動物 |
| JP2019130027A Active JP6942757B2 (ja) | 2012-02-01 | 2019-07-12 | Ｖｌドメインを含む重鎖を発現するヒト化齧歯動物 |
| JP2021099420A Active JP7187615B2 (ja) | 2012-02-01 | 2021-06-15 | Ｖｌドメインを含む重鎖を発現するヒト化齧歯動物 |
| JP2022191963A Active JP7525579B2 (ja) | 2012-02-01 | 2022-11-30 | Ｖｌドメインを含む重鎖を発現するヒト化齧歯動物 |
| JP2023173593A Pending JP2023168590A (ja) | 2012-02-01 | 2023-10-05 | Ｖｌドメインを含む重鎖を発現するヒト化齧歯動物 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018022012A Active JP6698718B2 (ja) | 2012-02-01 | 2018-02-09 | Ｖｌドメインを含む重鎖を発現するヒト化齧歯動物 |
| JP2019130027A Active JP6942757B2 (ja) | 2012-02-01 | 2019-07-12 | Ｖｌドメインを含む重鎖を発現するヒト化齧歯動物 |
| JP2021099420A Active JP7187615B2 (ja) | 2012-02-01 | 2021-06-15 | Ｖｌドメインを含む重鎖を発現するヒト化齧歯動物 |
| JP2022191963A Active JP7525579B2 (ja) | 2012-02-01 | 2022-11-30 | Ｖｌドメインを含む重鎖を発現するヒト化齧歯動物 |
| JP2023173593A Pending JP2023168590A (ja) | 2012-02-01 | 2023-10-05 | Ｖｌドメインを含む重鎖を発現するヒト化齧歯動物 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US20130212719A1 (enExample) |
| EP (3) | EP3597038B1 (enExample) |
| JP (6) | JP2015505477A (enExample) |
| KR (2) | KR20140123983A (enExample) |
| CN (2) | CN106117364B (enExample) |
| AU (3) | AU2013204758B2 (enExample) |
| BR (1) | BR112014018843B1 (enExample) |
| CA (1) | CA2863175A1 (enExample) |
| CY (2) | CY1122419T1 (enExample) |
| DK (2) | DK2809150T3 (enExample) |
| ES (2) | ES2870703T3 (enExample) |
| HR (2) | HRP20192218T1 (enExample) |
| HU (2) | HUE055610T2 (enExample) |
| IL (3) | IL233827A0 (enExample) |
| LT (2) | LT2809150T (enExample) |
| ME (1) | ME03611B (enExample) |
| MX (2) | MX373286B (enExample) |
| NZ (5) | NZ793447A (enExample) |
| PL (2) | PL2809150T3 (enExample) |
| PT (2) | PT3597038T (enExample) |
| RS (2) | RS59699B1 (enExample) |
| RU (2) | RU2770016C2 (enExample) |
| SG (3) | SG10201606256TA (enExample) |
| SI (2) | SI2809150T1 (enExample) |
| SM (2) | SMT202100401T1 (enExample) |
| WO (1) | WO2013116609A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2669298A3 (en) * | 2008-05-23 | 2014-02-26 | Ablexis, LLC | Single variable immunoglobulin domain comprising VL-DH-JL |
| DK3622815T3 (da) | 2009-07-08 | 2023-06-26 | Kymab Ltd | Gnavermodeller og terapeutiske molekyler |
| US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
| SMT201700023T1 (it) | 2010-08-02 | 2017-03-08 | Regeneron Pharma | Topi che producono proteine leganti vl |
| HUE047278T2 (hu) | 2011-08-05 | 2020-04-28 | Regeneron Pharma | Humanizált univerzális könnyûláncú egerek |
| BR112014006394A2 (pt) | 2011-09-19 | 2017-03-28 | Kymab Ltd | manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos |
| WO2013045916A1 (en) | 2011-09-26 | 2013-04-04 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| GB201122047D0 (en) * | 2011-12-21 | 2012-02-01 | Kymab Ltd | Transgenic animals |
| SG10201605675WA (en) | 2011-12-20 | 2016-09-29 | Regeneron Pharma | Humanized light chain mice |
| EP3597038B1 (en) * | 2012-02-01 | 2021-04-21 | Regeneron Pharmaceuticals, Inc. | Humanized rodents that express heavy chains containing vl domains |
| US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| ME03551B (me) | 2012-06-12 | 2020-07-20 | Regeneron Pharma | Humanizovane nehumane živoтinje sa ograničenim lokusima imunoglobulinskog тeškog lanca |
| MY178882A (en) | 2013-02-20 | 2020-10-21 | Regeneron Pharma | Non-human animals with modified immunoglobulin heavy chain sequences |
| US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
| US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
| US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| AU2014330922A1 (en) | 2013-10-01 | 2016-03-03 | Kymab Limited | Animal models and therapeutic molecules |
| CA3124228C (en) | 2014-03-21 | 2024-05-14 | Regeneron Pharmaceuticals, Inc. | Non-human animals that make single domain binding proteins |
| AU2015231025A1 (en) | 2014-03-21 | 2016-09-15 | Regeneron Pharmaceuticals, Inc. | Vl antigen binding proteins exhibiting distinct binding characteristics |
| CA2979702A1 (en) * | 2015-03-19 | 2016-09-22 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
| CA2981077A1 (en) * | 2015-04-03 | 2016-10-06 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of b-cells |
| JP2019513415A (ja) * | 2016-04-04 | 2019-05-30 | イーティーエッチ チューリッヒ | タンパク質産生及びライブラリー生成のための哺乳類細胞株 |
| CN113831407B (zh) | 2016-05-20 | 2024-06-11 | 瑞泽恩制药公司 | 用于使用多个引导rna来破坏免疫耐受性的方法 |
| US11089767B2 (en) * | 2017-03-30 | 2021-08-17 | Utah State University | Transgenic silkworms expressing spider silk |
| HUE060608T2 (hu) * | 2017-12-05 | 2023-03-28 | Regeneron Pharma | Genetikailag módosított immunglobulin lambda könnyûlánccal rendelkezõ egerek és azok alkalmazása |
| EP3772927B1 (en) * | 2018-03-24 | 2025-01-15 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice or rats for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof |
| IL318469A (en) * | 2018-06-14 | 2025-03-01 | Regeneron Pharma | Non-human animals capable of reorganizing transgenic DH-DH, and their uses |
| US20220090060A1 (en) | 2020-09-11 | 2022-03-24 | Regeneron Pharmaceuticals, Inc. | Identification and production of antigen-specific antibodies |
| CN116848254B (zh) | 2020-12-16 | 2026-03-17 | 瑞泽恩制药公司 | 表达人源化Fcα受体的小鼠 |
| CN114645042A (zh) * | 2020-12-18 | 2022-06-21 | 中国食品药品检定研究院 | 一种构建具有表达荧光素酶和红色荧光蛋白的重组巨噬细胞的转基因小鼠的方法 |
| CN114196626A (zh) * | 2022-02-16 | 2022-03-18 | 北京国卫生物科技有限公司 | 脐带间充质干细胞及其分离培养扩增方法 |
| KR20250108092A (ko) * | 2024-01-02 | 2025-07-15 | 젬파마테크 컴퍼니 리미티드 | 인간화 항체를 생성하는 동물 모델 및 그 제작 방법 |
| CN121065267A (zh) * | 2024-06-04 | 2025-12-05 | 赛业（苏州）生物科技有限公司 | 用于制备四元固定轻链的基因修饰的啮齿动物及其制备方法 |
| WO2026030428A2 (en) | 2024-08-01 | 2026-02-05 | Regeneron Pharmaceuticals, Inc. | Prostate-specific antigen peptides and uses thereof |
| WO2026035843A2 (en) | 2024-08-06 | 2026-02-12 | Regeneron Pharmaceuticals, Inc. | Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6774279B2 (en) | 1997-05-30 | 2004-08-10 | Carnegie Institution Of Washington | Use of FLP recombinase in mice |
| EA013564B1 (ru) * | 2000-08-03 | 2010-06-30 | Терапеутик Хьюман Поликлоналз Инк. | Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) * | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| CN101016543A (zh) * | 2000-11-17 | 2007-08-15 | 罗切斯特大学 | 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的多核苷酸的方法 |
| US7473557B2 (en) | 2001-06-06 | 2009-01-06 | Regeneron Pharmaceuticals, Inc. | Method for targeting transcriptionally active loci |
| DE60239420D1 (de) | 2001-12-21 | 2011-04-21 | Thrombogenics Nv | Zusammensetzungen für die in vitro herleitung und kultur embryonaler stammzellinien mit keimbahnübertragungsfähigkeit und für die kultur adulter stammzellen |
| AU2003230741A1 (en) * | 2002-03-22 | 2003-10-13 | Origen Therapeutics | Transgenic aves producing human polyclonal antibodies |
| ES2473596T3 (es) * | 2003-07-15 | 2014-07-07 | Therapeutic Human Polyclonals, Inc. | Loci de inmunoglobulina humanizada |
| ES2463476T3 (es) | 2004-10-19 | 2014-05-28 | Regeneron Pharmaceuticals, Inc. | Método para generar un ratón homocigótico para una modificación genética |
| US20080184380A1 (en) * | 2004-10-22 | 2008-07-31 | Therapeutic Human Polyclonals Inc. | Suppression of Endogenous Immunoglobulin Expression in Non-Human Transgenic Animals |
| AU2007235496B2 (en) * | 2006-03-31 | 2013-11-21 | E. R. Squibb & Sons, L.L.C. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
| PE20081216A1 (es) * | 2006-09-01 | 2008-09-04 | Therapeutic Human Polyclonals Inc | Expresion mejorada de la inmunoglobulina humana o humanizada en animales transgenicos no humanos |
| US8426565B2 (en) * | 2007-08-30 | 2013-04-23 | Walter And Eliza Hall Institute Of Medical Research | Dendritic cell marker and uses thereof |
| KR101680906B1 (ko) * | 2007-09-26 | 2016-11-30 | 추가이 세이야쿠 가부시키가이샤 | 항체 정상영역 개변체 |
| US7659842B2 (en) | 2007-10-24 | 2010-02-09 | Infineon Technologies Ag | Quantization error reduction in PWM full-MASH converters |
| EP2669298A3 (en) * | 2008-05-23 | 2014-02-26 | Ablexis, LLC | Single variable immunoglobulin domain comprising VL-DH-JL |
| EP2147594B1 (en) * | 2008-06-27 | 2013-11-13 | Merus B.V. | Antibody producing non-human mammals |
| CN102137928A (zh) * | 2008-08-29 | 2011-07-27 | 西福根有限公司 | 克隆禽源抗体的方法 |
| WO2010091182A2 (en) * | 2009-02-04 | 2010-08-12 | Molecular Innovations | Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin, and antibodies used therein |
| DK3622815T3 (da) * | 2009-07-08 | 2023-06-26 | Kymab Ltd | Gnavermodeller og terapeutiske molekyler |
| RU2425880C2 (ru) * | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
| CN103228130B (zh) * | 2010-06-17 | 2016-03-16 | 科马布有限公司 | 动物模型及治疗分子 |
| SMT201700023T1 (it) * | 2010-08-02 | 2017-03-08 | Regeneron Pharma | Topi che producono proteine leganti vl |
| ME02106B (me) * | 2011-02-25 | 2015-10-20 | Regeneron Pharma | Miševi sa adam6 |
| HUE047278T2 (hu) * | 2011-08-05 | 2020-04-28 | Regeneron Pharma | Humanizált univerzális könnyûláncú egerek |
| SG10201605675WA (en) * | 2011-12-20 | 2016-09-29 | Regeneron Pharma | Humanized light chain mice |
| EP3597038B1 (en) * | 2012-02-01 | 2021-04-21 | Regeneron Pharmaceuticals, Inc. | Humanized rodents that express heavy chains containing vl domains |
| ME03551B (me) * | 2012-06-12 | 2020-07-20 | Regeneron Pharma | Humanizovane nehumane živoтinje sa ograničenim lokusima imunoglobulinskog тeškog lanca |
| SG10201913483XA (en) * | 2016-11-04 | 2020-03-30 | Regeneron Pharma | Non-human animals having an engineered immunoglobulin lambda light chain locus |
-
2013
- 2013-02-01 EP EP19191081.9A patent/EP3597038B1/en active Active
- 2013-02-01 CA CA2863175A patent/CA2863175A1/en active Pending
- 2013-02-01 CN CN201610371631.3A patent/CN106117364B/zh active Active
- 2013-02-01 AU AU2013204758A patent/AU2013204758B2/en active Active
- 2013-02-01 MX MX2019002517A patent/MX373286B/es active IP Right Grant
- 2013-02-01 KR KR1020147024417A patent/KR20140123983A/ko not_active Ceased
- 2013-02-01 SM SM20210401T patent/SMT202100401T1/it unknown
- 2013-02-01 RS RS20191615A patent/RS59699B1/sr unknown
- 2013-02-01 NZ NZ793447A patent/NZ793447A/en unknown
- 2013-02-01 RS RS20210791A patent/RS62023B1/sr unknown
- 2013-02-01 EP EP21167681.2A patent/EP3912465A1/en active Pending
- 2013-02-01 SG SG10201606256TA patent/SG10201606256TA/en unknown
- 2013-02-01 NZ NZ734504A patent/NZ734504A/en unknown
- 2013-02-01 HU HUE19191081A patent/HUE055610T2/hu unknown
- 2013-02-01 RU RU2018122695A patent/RU2770016C2/ru active
- 2013-02-01 NZ NZ627977A patent/NZ627977A/en active IP Right Revival
- 2013-02-01 PL PL13704329T patent/PL2809150T3/pl unknown
- 2013-02-01 LT LT13704329T patent/LT2809150T/lt unknown
- 2013-02-01 SG SG11201404477YA patent/SG11201404477YA/en unknown
- 2013-02-01 DK DK13704329T patent/DK2809150T3/da active
- 2013-02-01 SG SG10201913428QA patent/SG10201913428QA/en unknown
- 2013-02-01 DK DK19191081.9T patent/DK3597038T3/da active
- 2013-02-01 ME MEP-2019-348A patent/ME03611B/me unknown
- 2013-02-01 RU RU2014133653A patent/RU2664185C2/ru active
- 2013-02-01 JP JP2014555736A patent/JP2015505477A/ja not_active Withdrawn
- 2013-02-01 BR BR112014018843-2A patent/BR112014018843B1/pt active IP Right Grant
- 2013-02-01 KR KR1020187037872A patent/KR20190006029A/ko not_active Ceased
- 2013-02-01 HU HUE13704329A patent/HUE046744T2/hu unknown
- 2013-02-01 PL PL19191081T patent/PL3597038T3/pl unknown
- 2013-02-01 SM SM20190685T patent/SMT201900685T1/it unknown
- 2013-02-01 PT PT191910819T patent/PT3597038T/pt unknown
- 2013-02-01 US US13/756,889 patent/US20130212719A1/en not_active Abandoned
- 2013-02-01 CN CN201380017544.2A patent/CN104202971B/zh active Active
- 2013-02-01 HR HRP20192218TT patent/HRP20192218T1/hr unknown
- 2013-02-01 MX MX2020003491A patent/MX2020003491A/es unknown
- 2013-02-01 LT LTEP19191081.9T patent/LT3597038T/lt unknown
- 2013-02-01 ES ES19191081T patent/ES2870703T3/es active Active
- 2013-02-01 EP EP13704329.5A patent/EP2809150B1/en active Active
- 2013-02-01 PT PT137043295T patent/PT2809150T/pt unknown
- 2013-02-01 WO PCT/US2013/024295 patent/WO2013116609A1/en not_active Ceased
- 2013-02-01 NZ NZ719228A patent/NZ719228A/en unknown
- 2013-02-01 SI SI201331592T patent/SI2809150T1/sl unknown
- 2013-02-01 ES ES13704329T patent/ES2753774T3/es active Active
- 2013-02-01 SI SI201331882T patent/SI3597038T1/sl unknown
- 2013-02-01 NZ NZ810648A patent/NZ810648A/en unknown
-
2014
- 2014-07-27 IL IL233827A patent/IL233827A0/en active IP Right Grant
-
2015
- 2015-10-23 AU AU2015246154A patent/AU2015246154B2/en active Active
-
2016
- 2016-10-14 US US15/294,488 patent/US20170094955A1/en not_active Abandoned
-
2017
- 2017-10-27 AU AU2017251848A patent/AU2017251848B2/en active Active
-
2018
- 2018-02-09 JP JP2018022012A patent/JP6698718B2/ja active Active
- 2018-08-21 IL IL261280A patent/IL261280B/en active IP Right Grant
-
2019
- 2019-07-12 JP JP2019130027A patent/JP6942757B2/ja active Active
- 2019-08-13 IL IL268675A patent/IL268675B/en active IP Right Grant
- 2019-12-10 CY CY20191101302T patent/CY1122419T1/el unknown
-
2021
- 2021-04-07 US US17/224,524 patent/US20210368751A1/en not_active Abandoned
- 2021-06-15 JP JP2021099420A patent/JP7187615B2/ja active Active
- 2021-06-23 HR HRP20210987TT patent/HRP20210987T1/hr unknown
- 2021-07-20 CY CY20211100659T patent/CY1124361T1/el unknown
-
2022
- 2022-11-30 JP JP2022191963A patent/JP7525579B2/ja active Active
-
2023
- 2023-10-05 JP JP2023173593A patent/JP2023168590A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015505477A5 (enExample) | ||
| JP2015502177A5 (enExample) | ||
| JP2015519076A5 (enExample) | ||
| RU2014127339A (ru) | Мыши с гуманизированной легкой цепью | |
| RU2014133653A (ru) | Гуманизированные грызуны, которые экспрессируют тяжелые цепи, содержащие домены vl | |
| JP2018138047A5 (enExample) | ||
| JP2014524243A5 (enExample) | ||
| JP2020501516A5 (enExample) | ||
| HRP20201403T1 (hr) | Neljudske životinje koje imaju genetski modificiran lokus imunoglobulinskog lambda lakog lanca | |
| JP2021137030A5 (enExample) | ||
| JP2014110814A5 (enExample) | ||
| RU2014153673A (ru) | Гуманизированные не относящиеся к человеку животные с ограниченными локусами тяжелой цепи иммуноглобулина | |
| JP2019047806A5 (enExample) | ||
| HRP20170322T1 (hr) | Miševi koji stvaraju vl vezne proteine | |
| JP2015509380A5 (enExample) | ||
| JP2013532974A5 (enExample) | ||
| JP2015525071A5 (enExample) | ||
| JP2011182801A5 (enExample) | ||
| JP2013535213A5 (enExample) | ||
| JP2015510767A5 (enExample) | ||
| RU2019121863A (ru) | Антитела со встроенным в легкие цепи гистидином и генетически модифицированные отличные от человека животные для их получения | |
| JP2020530760A5 (enExample) | ||
| HRP20230490T1 (hr) | Miševi koji izražavaju ograničeni repertoar lakog lanca imunoglobulina | |
| HRP20160497T1 (hr) | Mišji hibridni laki lanac | |
| HRP20171357T1 (hr) | Ograničeni teški lanac imunoglobulina u miševa |